Acuta Capital Partners’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Acuta Capital Partners’s Portfolio OXFD Stock Details OXFD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-386,100	Closed	-$5.98M	–	81
2017 Q1	$5.98M	Sell	386,100 -84,734	-18%	-$1.21M	1.42%	18
2016 Q4	$7.04M	Buy	470,834 +63,019	+15%	+$885K	2.62%	15
2016 Q3	$5.12M	Sell	407,815 -9,463	-2%	-$95K	1.92%	18
2016 Q2	$3.76M	Buy	417,278 +109,234	+35%	+$1.07M	1.8%	17
2016 Q1	$3.05M	Buy	308,044 +117,944	+62%	+$1.21M	1.71%	22
2015 Q4	$2.19M	Buy	190,100 +5,354	+3%	+$66.3K	1.05%	29
2015 Q3	$2.49M	Sell	184,746 -12,934	-7%	-$175K	1.44%	28
2015 Q2	$2.74M	Sell	197,680 -24,546	-11%	-$332K	1.69%	23
2015 Q1	$3.13M	Buy	+222,226	New	+$3.02M	2.64%	11

Other funds holding OXFD

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acuta Capital Partners's OXFD Position: Q2 2017 in Review

Acuta Capital Partners sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q2 2017, closing a stake of 386,100 shares — an estimated $5.98M sold.

Acuta Capital Partners first reported a position in OXFD in Q1 2015 and held it in 9 quarters. The position peaked at $7.04M in Q4 2016. 75 funds tracked by Wall St. Rank hold OXFD as of Q2 2017.

Acuta Capital Partners reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Acuta Capital Partners sold 386,100 Oxford Immunotec Global PLC Ordinary Shares shares in Q2 2017, an estimated $5.98M.
Acuta Capital Partners first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q1 2015 and held it in 9 quarters.
Acuta Capital Partners's Oxford Immunotec Global PLC Ordinary Shares position peaked at $7.04M in Q4 2016.
75 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q2 2017.

Based on Acuta Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.